Intellia Therapeutics (NASDAQ:NTLA) EVP James Basta Sells 10,397 Shares

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP James Basta sold 10,397 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $9.21, for a total transaction of $95,756.37. Following the completion of the transaction, the executive vice president directly owned 101,528 shares in the company, valued at approximately $935,072.88. This represents a 9.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Intellia Therapeutics Stock Performance

Shares of NTLA stock traded up $0.40 during trading hours on Wednesday, reaching $10.13. The company had a trading volume of 5,055,169 shares, compared to its average volume of 4,466,384. The company has a market capitalization of $1.17 billion, a P/E ratio of -2.37 and a beta of 2.05. The stock’s fifty day simple moving average is $9.58 and its 200 day simple moving average is $12.70. Intellia Therapeutics, Inc. has a twelve month low of $5.90 and a twelve month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.10. The business had revenue of $13.78 million during the quarter, compared to the consensus estimate of $14.12 million. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The business’s quarterly revenue was up 51.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.34) earnings per share. As a group, equities analysts expect that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

Several large investors have recently modified their holdings of the company. Headlands Technologies LLC bought a new position in Intellia Therapeutics in the 2nd quarter worth approximately $26,000. Blue Bell Private Wealth Management LLC acquired a new position in shares of Intellia Therapeutics in the third quarter valued at $30,000. Caitong International Asset Management Co. Ltd bought a new position in Intellia Therapeutics in the third quarter worth $30,000. Whipplewood Advisors LLC boosted its stake in Intellia Therapeutics by 114,900.0% during the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after buying an additional 3,447 shares in the last quarter. Finally, Advisory Services Network LLC bought a new stake in Intellia Therapeutics in the 3rd quarter valued at $33,000. 88.77% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

NTLA has been the subject of a number of research reports. Barclays decreased their price objective on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, November 7th. Tudor Pickering set a $14.50 price objective on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Sanford C. Bernstein set a $14.50 target price on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Guggenheim lowered Intellia Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, October 27th. Finally, Truist Financial reiterated a “buy” rating and issued a $14.00 target price (down previously from $25.00) on shares of Intellia Therapeutics in a report on Monday, November 10th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $18.43.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.